Drugs / ANAVEX3-71
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04442945 | Jul 2020 → Sep 2021 | — | Anavex Life Sciences Corp. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06245213 Comparator | Mar 2024 → Jun 2025 overdue | schizophrenia | Anavex Life Sciences Corp. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-02 | Anavex Life Sciences Corp. | Results Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program anavex.com ↗
Study results demonstrated a pharmacokinetic profile supportive of once-daily dosing with a safety profile consistent with prior ANAVEX®3-71 studies. |
| 2025-10-02 | Anavex Life Sciences Corp. | Results Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia anavex.com ↗
The study successfully achieved its primary endpoint, demonstrating that ANAVEX®3-71 was safe and well-tolerated. |
| 2024-10-17 | Anavex Life Sciences Corp. | Results Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia anavex.com ↗
Preliminary results demonstrated a dose-dependent effect of ANAVEX®3-71 on two key EEG biomarkers in patients with schizophrenia. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-02 | Anavex Life Sciences Corp. | Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program anavex.com ↗ |
| 2025-10-02 | Anavex Life Sciences Corp. | Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia anavex.com ↗ |
| 2024-10-17 | Anavex Life Sciences Corp. | Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia anavex.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANAVEX3-71 | “ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects.” NCT06245213 ↗ |
| Known as | AF710B | “ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects.” NCT06245213 ↗ |
| Action | Activate | “dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects” NCT06245213 ↗ |
| Route | Oral | “orally administered ANAVEX3-71” NCT04442945 ↗ |